AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01312259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis
Description: Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
Study NCT01312259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis
Description: Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
Study NCT00477503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gallium-67 Citrate (Ga-67)
Description: Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.
Study NCT00477503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: In-111 DTPA (In-111 pentetate)
Description: Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.
Study NCT01093677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIM-0705
Description: Oral solution 750 mg LIM 0705 BID for 14 days.
Study NCT02764437 — intervention group
Intervention type: BIOLOGICAL
Intervention: Whole lung antigen challenge, segmental allergen challenge
Description: Whole lung antigen challenge with housedust mite, short ragweed or cat hair allergen extracts. Segmental allergen challenge with housedust mite, short ragweed or cat hair allergen extracts.
Study NCT01699724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZoloft
Description: 50 mg tablet on Day 1 of each period
Study NCT01699724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline ODT
Description: 50 mg tablet on Day 1 of each period
Study NCT01316718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: 2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
Study NCT01316718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
Study NCT03993483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unilateral resistance exercise
Description: The participants performed three sets of their unilateral resistance exercise (biceps curls and knee extensions) three times per week for 10 weeks.
Study NCT02582333 — intervention group
Intervention type: OTHER
Intervention: Observation for clinical and virological changes
Description: Only observation after stopping nucleos(t)ide analogue
Study NCT00528307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIS buldle ablation
Description: HIS bundle ablation, followed by implant of a biventricular pacemaker
Study NCT03139552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple Crisp
Description: Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of apple crisp in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
Study NCT03139552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple Crisp
Description: Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of apple crisp in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
Study NCT03139552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tea
Description: Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of tea in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
Study NCT03139552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea
Description: Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of tea in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
Study NCT03139552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oatmeal
Description: Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe of oatmeal in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
Study NCT03139552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal
Description: Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe of oatmeal in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
Study NCT03204643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BH-VPN
Description: A bundle of usual care components, applied consistently and completely, along with access to behavioral health specific patient navigators and navigation services.
Study NCT00780975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aplidin (plitidepsin)
Description: Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.
Study NCT04525430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: childbirth education
Description: The 1st Session: General information about labor: Factors affecting labor, early signs of labor, signs of the start of labor, steps of labor, and procedures applied during labor.~The 2nd Session: Methods of coping with birth contractions: Breathing exercises, relaxation exercises, massage, changing position, music, cold/warm application, focus, and walking.
Study NCT04525430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: childbirth education and was subjected to a birth plan
Description: In the birth plan created by the researchers, the pregnant women considered the process from the start of labor to the end of labor and marked the expectation from and preferences about this process on the birth plan.
Study NCT00012025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Study NCT02700048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-nasal naloxone
Description: 3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
Study NCT02700048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-nasal saline
Description: 3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
Study NCT03247777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional strengthening
Description: dead lifts, bench press, wrist curls, and lat pulldowns as examples
Study NCT03247777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Strengthening
Description: diagonal chops, one leg deadlifts, lateral plyometrics as examples
Study NCT02946359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib, bevacizumab
Description: Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
Study NCT02340000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose amoxicillin/clavulanate
Description: amoxicillin/clavulanate 875/125 + placebo bid x 7 days
Study NCT02340000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose amoxicillin/clavulanate
Description: Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days
Study NCT04191889 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
Description: Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets~Procedure:~1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on day 8 in the first HAIC cycle, once a day, for continuous medication.~3. The first dose of Camrelizumab was administered on day 4 of the second HAIC cycle, at a dose of 200 mg intravenously, every three weeks.~4. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear.
Study NCT04549493 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure Therapy
Description: Exposure Therapy is used to reduce the symptoms of PTSD
Study NCT02404051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg daily tablets
Study NCT02404051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg daily tablets
Study NCT02404051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
Study NCT00492726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Moxifloxacin, 400mg, administered intravenously once daily
Study NCT00492726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem intravenous
Description: Active treatment: Ertapenem 1.0g, administered intravenously once daily
Study NCT01604889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Study NCT01604889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01604889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ipilimumab
Description: ipilimumab 3 mg/kg IV
Study NCT01604889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Doses to be determined following the completion of Phase I of the study
Study NCT00456872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Study NCT00144599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Study NCT00144599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01039766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: A single intranasal administration of 40 IU of oxytocin will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months.
Study NCT01039766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo - saline nasal spray
Description: A single intranasal administration of saline will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months as the control to the oxytocin arm
Study NCT02230891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol is a non selective beta blocker
Study NCT02230891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
Study NCT02230891 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: standard care as per primary care provider
Study NCT04804176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-low frequency repetitive transcranial magnetic stimulation
Description: Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
Study NCT04804176 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultra-low frequency repetitive transcranial magnetic stimulation
Description: Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
Study NCT03912038 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: No intervention
Study NCT01441973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608; HuLuc63)
Study NCT03912740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients in the dexmedetomidine-remifentanil group will receive an infusion of 0.6 mcg/kg in half an hour followed by an infusion of 0.6 mcg/kg/hour.
Study NCT03912740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride
Description: Patients in the remifentanil group will receive an infusion of 0.9% sodium chloride instead of dexmedetomidine (identical infusion rate)
Study NCT03912740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Both groups will have remifentanil analgesia guided by the Nol-Index
Study NCT01093677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution placebo BID for 14 days.
Study NCT00978367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: 5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
Study NCT00978367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: 5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
Study NCT00978367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avotermin
Description: 5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
Study NCT00978367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
Study NCT00978367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
Study NCT00978367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
Study NCT01428375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (1) Paracetamol injection
Description: Drugs: (1) Bottle containing 1000 mg Paracetamol in 100 ml solution for intravenous infusion
Study NCT01428375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Drugs: (2) Bottle containing 100 ml sterile water for intravenous infusion
Study NCT01857089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotest CE
Description: Orthotest CE is a rigid base mapping system composed by 1024 pressure transducers uniformly distributed in a 35x35 cm surface.~Orthotest CE is a product manufactured by Vista-Medical. The patient sit on the rigid base during 2 hours to record the pressure and all the data needed for the pilot study.~Pressure measurement
Study NCT01484600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN668: Injection Rate 1
Description: Subjects will receive REGN668 via SC injection
Study NCT01484600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN668: Injection Rate 2
Description: Subjects will receive study drug via alternate delivery (if necessary)
Study NCT04590157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Laser Acupuncture application on Neurogenic Acupoints: the treatment based upon the use of low power laser light to stimulate acupuncture points
Study NCT04590157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: exercise prodram as follow: from supine lying position with legs slightly apart the patient asked to contract the pelvic muscles as hard as possible and hold for 10 seconds
Study NCT01620918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: normal healing abutment
Description: Patient receives the normal, uncoated healing abutment on 1 of his (minimal 2) dental implants.
Study NCT01620918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nano-structured healing abutment
Description: Patient receives the nano-structured healing abutment on 1 of his (minimal 2) dental implants.
Study NCT02207855 — intervention group
Intervention type: DRUG
Intervention: Chloroprocaine
Study NCT02745353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxegol
Study NCT02305277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (clinical micronized, CM)
Study NCT02305277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (to-be-marketed, TBM)
Study NCT01526408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famciclovir
Description: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).
Study NCT01526408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
Study NCT00994747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutramigen (Flavor and Type of Infant Formula)
Description: Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life
Study NCT00994747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enfamil, milk-based formula
Description: Enfamil, milk-based formula, fed as formula source during first 8.5 months of life
Study NCT01702909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2